title: Childhood nail psoriasis: a useful treatment with tazarotene 0.05%.
abstract: Nail psoriasis occurs in 7% to 40% of children, with a similar pattern of clinical presentation to that of adults. In 0.6% to 2.3% of the patients nail changes appear as the only sign of the disease, preceding other skin and articular involvement. No pediatric clinical trials are available yet, but considering the successful use of tazarotene for nail dystrophy therapy in adults, we chose this drug to treat a child.
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Rome, Italy. lauradiluvio@yahoo.it
authors.forename: Laura
authors.initials: L
authors.lastname: Diluvio
authors.forename: Elena
authors.initials: E
authors.lastname: Campione
authors.forename: Evelin J
authors.initials: EJ
authors.lastname: Paternò
authors.forename: Cristina
authors.initials: C
authors.lastname: Mordenti
authors.forename: Maya
authors.initials: M
authors.lastname: El Hachem
authors.forename: Sergio
authors.initials: S
authors.lastname: Chimenti
mesh_terms: D002648:Child; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009260:Nail Diseases / Q000188:drug therapy*; D009539:Nicotinic Acids / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D012176:Retinoids
chemical_list: D003879:Dermatologic Agents; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids